Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Corrigendum to "Effect of levetiracetam on extracellular amino acid levels in the dorsal hippocampus of rats with temporal lobe epilepsy" [Epilepsy Res. 140 (2018) 111-119].

Epilepsy research

Pichardo Macías LA, Ramírez Mendiola BA, Contreras García IJ, Zamudio Hernández SR, Chávez Pacheco JL, Sánchez Huerta KB, Mendoza Torreblanca JG.
PMID: 30442383
Epilepsy Res. 2019 Jan;149:124. doi: 10.1016/j.eplepsyres.2018.10.015. Epub 2018 Nov 12.

No abstract available.

Cite
Pichardo Macías LA, Ramírez Mendiola BA, Contreras García IJ, et al. Corrigendum to "Effect of levetiracetam on extracellular amino acid levels in the dorsal hippocampus of rats with temporal lobe epilepsy" [Epilepsy Res. 140 (2018) 111-119]. Epilepsy Res. 2018;149:124doi: 10.1016/j.eplepsyres.2018.10.015.
Pichardo Macías, L. A., Ramírez Mendiola, B. A., Contreras García, I. J., Zamudio Hernández, S. R., Chávez Pacheco, J. L., Sánchez Huerta, K. B., & Mendoza Torreblanca, J. G. (2019). Corrigendum to "Effect of levetiracetam on extracellular amino acid levels in the dorsal hippocampus of rats with temporal lobe epilepsy" [Epilepsy Res. 140 (2018) 111-119]. Epilepsy research, 149124. https://doi.org/10.1016/j.eplepsyres.2018.10.015
Pichardo Macías, Luz Adriana, et al. "Corrigendum to "Effect of levetiracetam on extracellular amino acid levels in the dorsal hippocampus of rats with temporal lobe epilepsy" [Epilepsy Res. 140 (2018) 111-119]." Epilepsy research vol. 149 (2019): 124. doi: https://doi.org/10.1016/j.eplepsyres.2018.10.015
Pichardo Macías LA, Ramírez Mendiola BA, Contreras García IJ, Zamudio Hernández SR, Chávez Pacheco JL, Sánchez Huerta KB, Mendoza Torreblanca JG. Corrigendum to "Effect of levetiracetam on extracellular amino acid levels in the dorsal hippocampus of rats with temporal lobe epilepsy" [Epilepsy Res. 140 (2018) 111-119]. Epilepsy Res. 2019 Jan;149:124. doi: 10.1016/j.eplepsyres.2018.10.015. Epub 2018 Nov 12. PMID: 30442383.
Copy Download .nbib Format: NLM
Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors.

Frontiers in pediatrics

Torres-Espíndola LM, Demetrio-Ríos J, Carmona-Aparicio L, Galván-Díaz C, Pérez-García M, Chávez-Pacheco JL, Granados-Montiel J, Torres-Ramírez de Arellano I, Aquino-Gálvez A, Castillejos-López MJ.
PMID: 30881949
Front Pediatr. 2019 Mar 01;7:48. doi: 10.3389/fped.2019.00048. eCollection 2019.

No abstract available.

Cite
Torres-Espíndola LM, Demetrio-Ríos J, Carmona-Aparicio L, et al. Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors. Front Pediatr. 2019;7:48doi: 10.3389/fped.2019.00048.
Torres-Espíndola, L. M., Demetrio-Ríos, J., Carmona-Aparicio, L., Galván-Díaz, C., Pérez-García, M., Chávez-Pacheco, J. L., Granados-Montiel, J., Torres-Ramírez de Arellano, I., Aquino-Gálvez, A., & Castillejos-López, M. J. (2019). Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors. Frontiers in pediatrics, 748. https://doi.org/10.3389/fped.2019.00048
Torres-Espíndola, Luz María, et al. "Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors." Frontiers in pediatrics vol. 7 (2019): 48. doi: https://doi.org/10.3389/fped.2019.00048
Torres-Espíndola LM, Demetrio-Ríos J, Carmona-Aparicio L, Galván-Díaz C, Pérez-García M, Chávez-Pacheco JL, Granados-Montiel J, Torres-Ramírez de Arellano I, Aquino-Gálvez A, Castillejos-López MJ. Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors. Front Pediatr. 2019 Mar 01;7:48. doi: 10.3389/fped.2019.00048. eCollection 2019. PMID: 30881949; PMCID: PMC6405632.
Copy Download .nbib Format: NLM
Comparative Bioavailability and Pharmacokinetics Between the Solid Form of Metformin vs a Novel Liquid Extemporaneous Formulation in Children.

Dose-response : a publication of International Hormesis Society

Alemón-Medina R, Altamirano-Bustamante N, Lugo-Goytia G, García-Álvarez R, Rivera-Espinosa L, Torres-Espíndola LM, Chávez-Pacheco JL, Juárez-Olguín H, Gómez-Garduño J, Flores-Pérez C, Fernández-Pérez PG.
PMID: 34602916
Dose Response. 2021 Sep 27;19(3):15593258211033140. doi: 10.1177/15593258211033140. eCollection 2021.

Metformin pharmacokinetics in a liquid extemporaneous formulation from commercial tablets was determined in paediatric patients. A randomized, transversal clinical trial was conducted in 34 children and adolescents between 7 and 17 years of age. 17 children were randomized to...

Cite
Alemón-Medina R, Altamirano-Bustamante N, Lugo-Goytia G, et al. Comparative Bioavailability and Pharmacokinetics Between the Solid Form of Metformin vs a Novel Liquid Extemporaneous Formulation in Children. Dose Response. 2021;19(3):15593258211033140doi: 10.1177/15593258211033140.
Alemón-Medina, R., Altamirano-Bustamante, N., Lugo-Goytia, G., García-Álvarez, R., Rivera-Espinosa, L., Torres-Espíndola, L. M., Chávez-Pacheco, J. L., Juárez-Olguín, H., Gómez-Garduño, J., Flores-Pérez, C., & Fernández-Pérez, P. G. (2021). Comparative Bioavailability and Pharmacokinetics Between the Solid Form of Metformin vs a Novel Liquid Extemporaneous Formulation in Children. Dose-response : a publication of International Hormesis Society, 19(3), 15593258211033140. https://doi.org/10.1177/15593258211033140
Alemón-Medina, Radamés, et al. "Comparative Bioavailability and Pharmacokinetics Between the Solid Form of Metformin vs a Novel Liquid Extemporaneous Formulation in Children." Dose-response : a publication of International Hormesis Society vol. 19,3 (2021): 15593258211033140. doi: https://doi.org/10.1177/15593258211033140
Alemón-Medina R, Altamirano-Bustamante N, Lugo-Goytia G, García-Álvarez R, Rivera-Espinosa L, Torres-Espíndola LM, Chávez-Pacheco JL, Juárez-Olguín H, Gómez-Garduño J, Flores-Pérez C, Fernández-Pérez PG. Comparative Bioavailability and Pharmacokinetics Between the Solid Form of Metformin vs a Novel Liquid Extemporaneous Formulation in Children. Dose Response. 2021 Sep 27;19(3):15593258211033140. doi: 10.1177/15593258211033140. eCollection 2021. PMID: 34602916; PMCID: PMC8481739.
Copy Download .nbib Format: NLM
The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.

Journal of clinical pharmacy and therapeutics

Flores-Pérez C, Castillejos-López MJ, Chávez-Pacheco JL, Dávila-Borja VM, Flores-Pérez J, Zárate-Castañón P, Acosta-Bastidas M, Cruz-Escobar J, Torres-Espíndola LM.
PMID: 33638195
J Clin Pharm Ther. 2021 Jun;46(3):633-639. doi: 10.1111/jcpt.13388. Epub 2021 Feb 26.

WHAT IS KNOWN AND OBJECTIVE: Midazolam is a drug that is metabolized by cytochrome P450 (CYP450) enzymes, particularly CYP3A4 and CYP3A5. The presence of single-nucleotide polymorphisms (SNPs) in the genes encoding these enzymes, such as CYP3A4*1B which is associated...

Cite
Flores-Pérez C, Castillejos-López MJ, Chávez-Pacheco JL, et al. The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients. J Clin Pharm Ther. 2021;46(3):633-639doi: 10.1111/jcpt.13388.
Flores-Pérez, C., Castillejos-López, M. J., Chávez-Pacheco, J. L., Dávila-Borja, V. M., Flores-Pérez, J., Zárate-Castañón, P., Acosta-Bastidas, M., Cruz-Escobar, J., & Torres-Espíndola, L. M. (2021). The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients. Journal of clinical pharmacy and therapeutics, 46(3), 633-639. https://doi.org/10.1111/jcpt.13388
Flores-Pérez, Carmen, et al. "The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients." Journal of clinical pharmacy and therapeutics vol. 46,3 (2021): 633-639. doi: https://doi.org/10.1111/jcpt.13388
Flores-Pérez C, Castillejos-López MJ, Chávez-Pacheco JL, Dávila-Borja VM, Flores-Pérez J, Zárate-Castañón P, Acosta-Bastidas M, Cruz-Escobar J, Torres-Espíndola LM. The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients. J Clin Pharm Ther. 2021 Jun;46(3):633-639. doi: 10.1111/jcpt.13388. Epub 2021 Feb 26. PMID: 33638195.
Copy Download .nbib Format: NLM
Intestinal permeability in a patient with liver cirrhosis.

Therapeutics and clinical risk management

Aguirre Valadez JM, Rivera-Espinosa L, Méndez-Guerrero O, Chávez-Pacheco JL, García Juárez I, Torre A.
PMID: 27920543
Ther Clin Risk Manag. 2016 Nov 18;12:1729-1748. doi: 10.2147/TCRM.S115902. eCollection 2016.

Liver cirrhosis is a worldwide public health problem, and patients with this disease are at high risk of developing complications, bacterial translocation from the intestinal lumen to the mesenteric nodes, and systemic circulation, resulting in the development of severe...

Cite
Aguirre Valadez JM, Rivera-Espinosa L, Méndez-Guerrero O, et al. Intestinal permeability in a patient with liver cirrhosis. Ther Clin Risk Manag. 2016;12:1729-1748doi: 10.2147/TCRM.S115902.
Aguirre Valadez, J. M., Rivera-Espinosa, L., Méndez-Guerrero, O., Chávez-Pacheco, J. L., García Juárez, I., & Torre, A. (2016). Intestinal permeability in a patient with liver cirrhosis. Therapeutics and clinical risk management, 121729-1748. https://doi.org/10.2147/TCRM.S115902
Aguirre Valadez, Jonathan Manuel, et al. "Intestinal permeability in a patient with liver cirrhosis." Therapeutics and clinical risk management vol. 12 (2016): 1729-1748. doi: https://doi.org/10.2147/TCRM.S115902
Aguirre Valadez JM, Rivera-Espinosa L, Méndez-Guerrero O, Chávez-Pacheco JL, García Juárez I, Torre A. Intestinal permeability in a patient with liver cirrhosis. Ther Clin Risk Manag. 2016 Nov 18;12:1729-1748. doi: 10.2147/TCRM.S115902. eCollection 2016. PMID: 27920543; PMCID: PMC5125722.
Copy Download .nbib Format: NLM
A 20-year retrospective study of osteoarticular tuberculosis in a pediatric third level referral center.

BMC pulmonary medicine

González Saldaña N, Macías Parra M, Xochihua Díaz L, Palavicini Rueda M, Carmona Vargas AJ, Castillo Bejarano JI, Veloz Corona Q, Juárez Olguín H, Chavez Pacheco JL.
PMID: 34399724
BMC Pulm Med. 2021 Aug 16;21(1):265. doi: 10.1186/s12890-021-01631-2.

PURPOSE: The objective of the present study is to describe the clinical, diagnostic, radiological and therapeutic aspects of osteoarticular tuberculosis (OATB) in patients in a tertiary pediatric hospital, to know if the diagnosis of OATB in pediatrics is a...

Cite
González Saldaña N, Macías Parra M, Xochihua Díaz L, et al. A 20-year retrospective study of osteoarticular tuberculosis in a pediatric third level referral center. BMC Pulm Med. 2021;21(1):265doi: 10.1186/s12890-021-01631-2.
González Saldaña, N., Macías Parra, M., Xochihua Díaz, L., Palavicini Rueda, M., Carmona Vargas, A. J., Castillo Bejarano, J. I., Veloz Corona, Q., Juárez Olguín, H., & Chavez Pacheco, J. L. (2021). A 20-year retrospective study of osteoarticular tuberculosis in a pediatric third level referral center. BMC pulmonary medicine, 21(1), 265. https://doi.org/10.1186/s12890-021-01631-2
González Saldaña, Napoleón, et al. "A 20-year retrospective study of osteoarticular tuberculosis in a pediatric third level referral center." BMC pulmonary medicine vol. 21,1 (2021): 265. doi: https://doi.org/10.1186/s12890-021-01631-2
González Saldaña N, Macías Parra M, Xochihua Díaz L, Palavicini Rueda M, Carmona Vargas AJ, Castillo Bejarano JI, Veloz Corona Q, Juárez Olguín H, Chavez Pacheco JL. A 20-year retrospective study of osteoarticular tuberculosis in a pediatric third level referral center. BMC Pulm Med. 2021 Aug 16;21(1):265. doi: 10.1186/s12890-021-01631-2. PMID: 34399724; PMCID: PMC8365951.
Copy Download .nbib Format: NLM
Buprenorphine and pain treatment in pediatric patients: an update.

Journal of pain research

Vicencio-Rosas E, Pérez-Guillé MG, Flores-Pérez C, Flores-Pérez J, Trujillo-Jiménez F, Chávez-Pacheco JL.
PMID: 29588613
J Pain Res. 2018 Mar 15;11:549-559. doi: 10.2147/JPR.S153903. eCollection 2018.

INTRODUCTION: The usual management of moderate to severe pain is based on the use of opioids. Buprenorphine (BPN) is an opioid with an analgesic potency 50 times greater than that of morphine. It is widely used in various pain...

Cite
Vicencio-Rosas E, Pérez-Guillé MG, Flores-Pérez C, et al. Buprenorphine and pain treatment in pediatric patients: an update. J Pain Res. 2018;11:549-559doi: 10.2147/JPR.S153903.
Vicencio-Rosas, E., Pérez-Guillé, M. G., Flores-Pérez, C., Flores-Pérez, J., Trujillo-Jiménez, F., & Chávez-Pacheco, J. L. (2018). Buprenorphine and pain treatment in pediatric patients: an update. Journal of pain research, 11549-559. https://doi.org/10.2147/JPR.S153903
Vicencio-Rosas, Erendira, et al. "Buprenorphine and pain treatment in pediatric patients: an update." Journal of pain research vol. 11 (2018): 549-559. doi: https://doi.org/10.2147/JPR.S153903
Vicencio-Rosas E, Pérez-Guillé MG, Flores-Pérez C, Flores-Pérez J, Trujillo-Jiménez F, Chávez-Pacheco JL. Buprenorphine and pain treatment in pediatric patients: an update. J Pain Res. 2018 Mar 15;11:549-559. doi: 10.2147/JPR.S153903. eCollection 2018. PMID: 29588613; PMCID: PMC5859905.
Copy Download .nbib Format: NLM
Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.

Brain sciences

Contreras-García IJ, Gómez-Lira G, Phillips-Farfán BV, Pichardo-Macías LA, García-Cruz ME, Chávez-Pacheco JL, Mendoza-Torreblanca JG.
PMID: 33922424
Brain Sci. 2021 Apr 23;11(5). doi: 10.3390/brainsci11050531.

Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy. Thus, changes in SV2A expression could be a critical...

Cite
Contreras-García IJ, Gómez-Lira G, Phillips-Farfán BV, et al. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Brain Sci. 2021;11(5)doi: 10.3390/brainsci11050531.
Contreras-García, I. J., Gómez-Lira, G., Phillips-Farfán, B. V., Pichardo-Macías, L. A., García-Cruz, M. E., Chávez-Pacheco, J. L., & Mendoza-Torreblanca, J. G. (2021). Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Brain sciences, 11(5), . https://doi.org/10.3390/brainsci11050531
Contreras-García, Itzel Jatziri, et al. "Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment." Brain sciences vol. 11,5 (2021). doi: https://doi.org/10.3390/brainsci11050531
Contreras-García IJ, Gómez-Lira G, Phillips-Farfán BV, Pichardo-Macías LA, García-Cruz ME, Chávez-Pacheco JL, Mendoza-Torreblanca JG. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Brain Sci. 2021 Apr 23;11(5). doi: 10.3390/brainsci11050531. PMID: 33922424; PMCID: PMC8145097.
Copy Download .nbib Format: NLM
Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension.

Diagnostics (Basel, Switzerland)

Baltazares-Lipp ME, Aguilera-Velasco A, Aquino-Gálvez A, Velázquez-Cruz R, Hernández-Zenteno RJ, Alvarado-Vásquez N, Camarena A, Sierra-Vargas MP, Chávez-Pacheco JL, Ruiz V, Salinas-Lara C, Tena-Suck ML, Romero Y, Torres-Espíndola LM, Castillejos-López M.
PMID: 34359380
Diagnostics (Basel). 2021 Jul 20;11(7). doi: 10.3390/diagnostics11071297.

Pulmonary hypertension is a rare condition that impairs patients' quality of life and life expectancy. The development of noninvasive instruments may help elucidate the prognosis of this cardiorespiratory disease. We aimed to evaluate the utility of routinely performed noninvasive...

Cite
Baltazares-Lipp ME, Aguilera-Velasco A, Aquino-Gálvez A, et al. Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension. Diagnostics (Basel). 2021;11(7)doi: 10.3390/diagnostics11071297.
Baltazares-Lipp, M. E., Aguilera-Velasco, A., Aquino-Gálvez, A., Velázquez-Cruz, R., Hernández-Zenteno, R. J., Alvarado-Vásquez, N., Camarena, A., Sierra-Vargas, M. P., Chávez-Pacheco, J. L., Ruiz, V., Salinas-Lara, C., Tena-Suck, M. L., Romero, Y., Torres-Espíndola, L. M., & Castillejos-López, M. (2021). Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension. Diagnostics (Basel, Switzerland), 11(7), . https://doi.org/10.3390/diagnostics11071297
Baltazares-Lipp, Mario E, et al. "Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension." Diagnostics (Basel, Switzerland) vol. 11,7 (2021). doi: https://doi.org/10.3390/diagnostics11071297
Baltazares-Lipp ME, Aguilera-Velasco A, Aquino-Gálvez A, Velázquez-Cruz R, Hernández-Zenteno RJ, Alvarado-Vásquez N, Camarena A, Sierra-Vargas MP, Chávez-Pacheco JL, Ruiz V, Salinas-Lara C, Tena-Suck ML, Romero Y, Torres-Espíndola LM, Castillejos-López M. Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension. Diagnostics (Basel). 2021 Jul 20;11(7). doi: 10.3390/diagnostics11071297. PMID: 34359380; PMCID: PMC8305029.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries